LAFAYETTE — Emily Toepfer gives herself a needle filled with insulin six times a day, but it doesn’t bother her.
“I get asked a lot if shots hurt, and personally, they don’t because I have had to do it for such a long time,” she said.
Emily, a seventh grader at Lafayette Township School, was diagnosed with type 1 diabetes, or T1D, as a fifth grader on Sept. 29, 2014.
Her blood sugar, or blood glucose, level had reached 734 mg — general medical guidelines are between 70 mg upon waking and less than 140 mg after eating — and she was rushed to the hospital.
“The doctors told me they couldn’t believe I was still alive,” Emily said.
Traces of skin, oil and grime left on your phone can reveal a lot about your lifestyle, and may some day serve as a “fingerprint” in criminal investigations, researchers said Monday.
The study involved 39 volunteers who allowed scientists to swab their smart phones — and right hands — in several places.
Researchers found a bounty of chemical information left behind on the devices.
These included anti-inflammatory and anti-fungal skin creams, hair loss treatments, anti-depressants and eye drops, according to the study in the Proceedings of the National Academy of Sciences.
They also found food molecules from citrus, caffeine, herbs and spices.
Sunscreen ingredients and DEET mosquito repellant were detected months after they had last been used by the phone owners.
“By analyzing the molecules they’ve left behind on their phones, we could tell if a person is likely female, uses high-end cosmetics, dyes her hair, drinks coffee, prefers beer over wine, likes spicy food, is being treated for depression, wears sunscreen and bug spray — and therefore likely spends a lot of time outdoors — all kinds of things,” said study co-author Amina Bouslimani of the University of California, San Diego.
Siemens AG agreed to buy Mentor Graphics Corp. for $4.5 billion in its biggest acquisition since 2014 as the German engineering company extends its industrial software capability.
Siemens will pay $37.25 a share for Wilsonville, Oregon-based Mentor, the industrial giant said in a statement on Monday. That’s 21 percent above the closing price on Friday. Elliott Management Corp., which owns 8.1 percent of Mentor’s shares, backs the offer, Siemens said.
The acquisition “will allow us to supplement our world-class industrial software portfolio,” Siemens board member Klaus Helmrich said in the statement. “It will complement our strong offering in mechanics and software with design, test and simulation of electrical and electronic systems.”
The deal follows the $970 million January purchaseof CD-adapco of the U.S. as Siemens seeks to grow its digital business as part of a retreat from consumer-oriented products to focus on industrial applications. Mentor is the biggest acquisition announced by Siemens since it agreed to buy Dresser-Rand Group Inc. for $7.6 billion. For its part, Mentor was under pressure to increase shareholder value from activist investor Elliott, which doubled its stake in Mentor in September.
Siemens shares rose 1.2 percent to 109.45 euros as of 9:14 a.m. in Frankfurt.
The purchase is expected to boost Siemens’s earnings before interest and taxes by more than 100 million euros ($108 million) within four years of closing and will contribute to earnings per share within three years, the company said.
Toyota will pay up to $3.4 billion to settle a class action lawsuit brought by US pickup and sport utility vehicle owners whose vehicles lacked adequate rust protection. Court filings show that the settlement reached Oct. 31 covers 1.5 million vehicles, dealing a financial blow to the Japanese automaker whose trucks were subject to corrosion that could harm their structural integrity. The settlement applies to Tacoma trucks made from 2005 to 2010, Sequoias from 2005 to 2008, and Tundras from 2007 to 2008. The settlement estimates the value of replacing the frame at roughly $15,000 per vehicle. Under the settlement, Toyota will inspect vehicles for 12 years from their initial sales or lease date to decide if the owner is eligible for a replaced frame or reimbursement. — ASSOCIATED PRESS
Pharmaceuticals
Arthritis pain drug found
to be safe
for the heart
A new study may reassure millions of arthritis sufferers seeking pain relief without bad side effects. It finds that Celebrex, a drug similar to ones withdrawn 12 years ago for safety reasons, is no riskier for the heart than some other painkillers that are tough on the stomach. The government required Pfizer, Celebrex’s maker, to do the safety study after the popular arthritis drug Vioxx was withdrawn. The study tested Celebrex against prescription-strength ibuprofen or naproxen in 24,000 people with heart disease or a high risk for it. The drugs proved similar on heart risks and Celebrex caused fewer stomach problems. Results were discussed Sunday at an American Heart Association conference and published by the New England Journal of Medicine.
— ASSOCIATED PRESS
The series will debut in the fall with the first two episodes debuting in Imax theaters in September.
Marvel has landed another series on ABC: The Inhumans.The comic book studio — which previously abandoned plans for an Inhumans feature film — is now set to team with ABC Studios for an eight-episode live-action drama series set to premiere in the fall of 2017.Few details are known about the project, including producers, cast and premise. The first two episodes of the series will debut in Imax theaters for two weeks in summer 2017 before moving to ABC in September where they will be followed by six subsequent new episodes.Sources note that this is not the planned Inhumans feature film, which was initially set for July 2019 but pulled from the schedule. It is also not a spinoff of Marvel drama Agents of SHIELD, which has spent a good deal of time exploring a storyline about its Inhumans.
‘Agent Carter’ Canceled at ABC; ‘Marvel’s Most Wanted’ Not Moving Forward
The Inhumans, a race of superhumans with diverse and singularly unique powers, were first introduced in Marvel Comics by Stan Lee and Jack Kirby in 1965. Since then, they have become among the most popular characters in the Marvel Universe.
ABC’s The Inhumans will explore the never-before-told epic adventure of Black Bolt and the royal family.
For ABC, this marks the latest Marvel drama to join the network’s schedule. The network last season canceled Agent Carter after two seasons and passed on a spinoff of Agents of SHIELD. Marvel, meanwhile, is teaming with Hulu on another comic book-based series that is in development and has a full slate of dramas at Netflix as well as upcoming X-Men spinoff Legion at FX, among other projects.
The big-screen version of The Inhumans was announced two years ago for a 2018 release. It was pushed back to 2019 as part of a shuffle to make room for Spider-Man: Homecoming, before being pulled from the schedule in April. Marvel had been positioning the Inhumans to be the Marvel Cinematic Universe’s answer to The X-Men. In recent comics, Marvel has portrayed them as a persecuted minority, similar to the Marvel mutant characters Fox has the film and TV rights to.
For Imax, this marks the first time a TV series has debuted in theaters in this fashion. Imax will also serve as a financing participant on the pilot. It’s also the first time a TV series has debuted in Imax.
